On October 2, 2023, Knowledge Ecology International submitted written comments to the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Medicare Price Negotiation public consultation process. CMS is hosting a series of patient-focused listening sessions this fall,… Continue Reading →
On September 12, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Universities Allied for Essential Medicines (UAEM), Social Security Works (SSW), and Clare Love filed an appeal with the National Institutes of Health (NIH). The signatories appealed… Continue Reading →
On Monday May 6, 2019, KEI gave the following intervention during the Department of Health and Human Services (HHS) Listening Session in advance of the Seventy-second World Health Assembly to be held in Geneva on May 20-28, 2019. KEI Statement… Continue Reading →
On April 19, 2019, HealthGap, Knowledge Ecology International, Public Citizen, Social Security Works and the Union for Affordable Cancer Treatment filed comments on a proposed license on National Cancer Institute patented inventions to Senti Bio, for a next generation CAR… Continue Reading →
KEI Comments on Medicare Programs: International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Knowledge Ecology International (KEI) is a non-profit organization that focuses on the management of knowledge goods, including new drugs, vaccines and other medical therapies. Much… Continue Reading →
The new House democrats medicare negotiations bill represents a turning point, with broad support for using robust compulsory licensing authority to protect access if negotiations on prices break down. The press conference announcing the bill featured several Democratic members of… Continue Reading →
On July 9, 2018, KEI asked the NIH to extend the deadline for comments described on the Federal Register notice 83 FR 30448 until information about the enrollment and costs of NIH-funded clinical trials involving mesothelin expressing cancers, and trials… Continue Reading →
Gilead 10-Q, 3rd quarter 2017 If any party is successful in establishing exclusive rights to axi-cel, our anticipated revenues and earnings from the sale of that product could be adversely affected. In October 2017, we acquired Kite, which is now… Continue Reading →
Attached (PDF file here) are the KEI comments on the proposed NIH exclusive license to miRecule for MicroRNA Therapeutics for Treating Squamous Cell Carcinomas.
The seven page letter concludes with these words:
Continue Reading →